CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade BioXcel Therapeutics, Inc. - BTAI CFD

3.18
0.95%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.04
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

BioXcel Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 3.15
Open* 3.19
1-Year Change* -90%
Day's Range* 3.15 - 3.25
52 wk Range 2.23-34.13
Average Volume (10 days) 425.70K
Average Volume (3 months) 58.64M
Market Cap 74.35M
P/E Ratio -100.00K
Shares Outstanding 29.27M
Revenue 1.24M
EPS -7.36
Dividend (Yield %) N/A
Beta 0.50
Next Earnings Date Mar 7, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 1, 2024 3.18 0.03 0.95% 3.15 3.27 3.13
Feb 29, 2024 3.15 -0.10 -3.08% 3.25 3.36 3.11
Feb 28, 2024 3.24 0.00 0.00% 3.24 3.42 3.20
Feb 27, 2024 3.31 0.26 8.52% 3.05 3.47 3.05
Feb 26, 2024 3.08 0.08 2.67% 3.00 3.13 2.94
Feb 23, 2024 3.07 0.02 0.66% 3.05 3.25 3.03
Feb 22, 2024 3.14 -0.02 -0.63% 3.16 3.30 3.10
Feb 21, 2024 3.13 -0.05 -1.57% 3.18 3.43 2.98
Feb 20, 2024 3.47 0.06 1.76% 3.41 3.76 3.41
Feb 16, 2024 3.49 -0.11 -3.06% 3.60 3.79 3.46
Feb 15, 2024 3.55 0.36 11.29% 3.19 3.57 3.12
Feb 14, 2024 3.09 0.66 27.16% 2.43 3.37 2.40
Feb 13, 2024 2.46 0.11 4.68% 2.35 2.62 2.06
Feb 12, 2024 1.92 -0.43 -18.30% 2.35 2.43 1.91
Feb 9, 2024 2.05 -0.26 -11.26% 2.31 2.31 1.87
Feb 8, 2024 3.73 0.09 2.47% 3.64 3.80 3.51
Feb 7, 2024 3.76 -0.12 -3.09% 3.88 3.90 3.58
Feb 6, 2024 4.01 0.51 14.57% 3.50 4.15 3.44
Feb 5, 2024 3.68 0.41 12.54% 3.27 3.84 3.14
Feb 2, 2024 3.04 -0.08 -2.56% 3.12 3.14 3.02

BioXcel Therapeutics, Inc. Events

Time (UTC) Country Event
Thursday, March 7, 2024

Time (UTC)

13:30

Country

US

Event

Q4 2023 BioXcel Therapeutics Inc Earnings Release
Q4 2023 BioXcel Therapeutics Inc Earnings Release

Forecast

-

Previous

-
Monday, May 6, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 BioXcel Therapeutics Inc Earnings Release
Q1 2024 BioXcel Therapeutics Inc Earnings Release

Forecast

-

Previous

-
Tuesday, June 25, 2024

Time (UTC)

13:00

Country

US

Event

BioXcel Therapeutics Inc Annual Shareholders Meeting
BioXcel Therapeutics Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0.375 0 0 0 0
Revenue 0.375 0 0 0 0
Total Operating Expense 160.02 106.935 82.297 33.601 19.962
Selling/General/Admin. Expenses, Total 68.761 54.227 24.302 7.804 5.404
Research & Development 91.239 52.708 57.995 25.797 14.558
Operating Income -159.645 -106.935 -82.297 -33.601 -19.962
Interest Income (Expense), Net Non-Operating -5.685 0.004 0.128 0.633 0.692
Net Income Before Taxes -165.757 -106.931 -82.169 -32.968 -19.27
Net Income After Taxes -165.757 -106.931 -82.169 -32.968 -19.27
Net Income Before Extra. Items -165.757 -106.931 -82.169 -32.968 -19.27
Net Income -165.757 -106.931 -82.169 -32.968 -19.27
Income Available to Common Excl. Extra. Items -165.757 -106.931 -82.169 -32.968 -19.27
Income Available to Common Incl. Extra. Items -165.757 -106.931 -82.169 -32.968 -19.27
Diluted Net Income -165.757 -106.931 -82.169 -32.968 -19.27
Diluted Weighted Average Shares 28.015 26.373 21.683 16.2892 14.5716
Diluted EPS Excluding Extraordinary Items -5.91672 -4.05456 -3.78956 -2.02392 -1.32244
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -5.91672 -4.05456 -3.78956 -2.02392 -1.32244
Cost of Revenue, Total 0.02
Gross Profit 0.355
Other, Net -0.427
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0.457 0.206 0.238 0.137 0
Revenue 0.457 0.206 0.238 0.137
Total Operating Expense 52.871 51.404 53.132 39.127 36.288
Selling/General/Admin. Expenses, Total 25.872 23.595 20.664 17.054 18.382
Research & Development 26.973 27.8 32.459 22.062 17.906
Operating Income -52.414 -51.198 -52.894 -38.99 -36.288
Interest Income (Expense), Net Non-Operating -1.638 -1.352 -1.434 -2.877 -1.382
Net Income Before Taxes -53.515 -52.796 -54.808 -41.805 -37.67
Net Income After Taxes -53.515 -52.796 -54.808 -41.805 -37.67
Net Income Before Extra. Items -53.515 -52.796 -54.808 -41.805 -37.67
Net Income -53.515 -52.796 -54.808 -41.805 -37.67
Income Available to Common Excl. Extra. Items -53.515 -52.796 -54.808 -41.805 -37.67
Income Available to Common Incl. Extra. Items -53.515 -52.796 -54.808 -41.805 -37.67
Diluted Net Income -53.515 -52.796 -54.808 -41.805 -37.67
Diluted Weighted Average Shares 29.187 28.616 28.069 28.022 27.989
Diluted EPS Excluding Extraordinary Items -1.83352 -1.84498 -1.95262 -1.49186 -1.34589
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -1.83352 -1.84498 -1.95262 -1.49186 -1.34589
Cost of Revenue, Total 0.026 0.009 0.009 0.011
Gross Profit 0.431 0.197 0.229 0.126
Other, Net 0.537 -0.246 -0.48 0.062
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 202.868 236.812 217.065 34.107 43.171
Cash and Short Term Investments 193.725 232.968 213.119 32.426 42.565
Cash & Equivalents 193.725 232.968 213.119 32.426 42.565
Prepaid Expenses 3.067 2.888 3.946 1.681 0.491
Total Assets 205.853 239.439 219.936 36.392 43.549
Property/Plant/Equipment, Total - Net 2.06 2.541 2.784 2.234 0.327
Property/Plant/Equipment, Total - Gross 2.945 3.143 3.146 2.408 0.345
Accumulated Depreciation, Total -0.885 -0.602 -0.362 -0.174 -0.018
Other Long Term Assets, Total 0.925 0.086 0.087 0.051 0.051
Total Current Liabilities 32.898 16.667 11.842 8.468 4.66
Accounts Payable 10.228 4.678 3.979 4.953 1.604
Accrued Expenses 22.081 11.483 7.009 3.284 3.056
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.589 0.506 0.854 0.231 0
Total Liabilities 129.078 17.772 13.24 9.497 4.66
Total Long Term Debt 93.051 0 0 0 0
Total Equity 76.775 221.667 206.696 26.895 38.889
Common Stock 0.028 0.028 0.024 0.018 0.016
Additional Paid-In Capital 488.292 467.427 345.529 83.565 62.593
Retained Earnings (Accumulated Deficit) -411.545 -245.788 -138.857 -56.688 -23.72
Other Equity, Total
Total Liabilities & Shareholders’ Equity 205.853 239.439 219.936 36.392 43.549
Total Common Shares Outstanding 28.147 27.98 24.417 18.0874 15.6632
Other Current Assets, Total 3.843 0.956 0 0.115
Other Liabilities, Total 3.129 1.105 1.398 1.029
Preferred Stock - Non Redeemable, Net 0 0
Total Receivables, Net 0.248
Accounts Receivable - Trade, Net 0.248
Total Inventory 1.985
Long Term Debt 93.051
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 98.738 138.235 177.268 202.868 241.661
Cash and Short Term Investments 89.961 127.545 165.521 193.725 232.314
Cash & Equivalents 89.961 127.545 165.521 193.725 232.314
Prepaid Expenses 3.853 3.698 4.506 3.067 5.509
Total Assets 100.449 140.097 180.103 205.853 244.818
Property/Plant/Equipment, Total - Net 1.624 1.775 1.91 2.06 2.232
Property/Plant/Equipment, Total - Gross 2.739 2.811 2.875 2.945 3.08
Accumulated Depreciation, Total -1.115 -1.036 -0.965 -0.885 -0.848
Other Long Term Assets, Total 0.087 0.087 0.925 0.925 0.925
Total Current Liabilities 39.408 34.744 28.759 32.898 23.378
Accounts Payable 10.669 11.203 7.742 10.228 5.872
Accrued Expenses 27.383 22.422 20.266 22.081 16.316
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 1.356 1.119 0.751 0.589 1.19
Total Liabilities 141.057 134.233 127.098 129.078 117.832
Total Long Term Debt 99.093 96.846 95.062 93.051 91.695
Other Liabilities, Total 2.556 2.643 3.277 3.129 2.759
Total Equity -40.608 5.864 53.005 76.775 126.986
Common Stock 0.029 0.029 0.029 0.028 0.028
Additional Paid-In Capital 527.705 523.691 517.317 488.292 483.695
Retained Earnings (Accumulated Deficit) -568.342 -517.856 -464.341 -411.545 -356.737
Total Liabilities & Shareholders’ Equity 100.449 140.097 180.103 205.853 244.818
Total Common Shares Outstanding 29.273 29.267 29.1 28.147 28.023
Other Current Assets, Total 2.171 4.636 5.006 3.843 2.43
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Total Inventory 2.018 1.925 1.952 1.985 1.408
Long Term Debt 99.093 96.846 95.062 93.051 91.695
Total Receivables, Net 0.735 0.431 0.283 0.248
Accounts Receivable - Trade, Net 0.735 0.431 0.283 0.248
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -165.757 -106.931 -82.169 -32.968 -19.27
Cash From Operating Activities -135.341 -82.153 -66.35 -27.101 -13.509
Cash From Operating Activities 0.327 0.297 0.188 0.156 0.017
Non-Cash Items 19.415 19.501 14.611 3.142 3.082
Changes in Working Capital 10.674 4.98 1.02 2.569 2.662
Cash From Investing Activities -0.139 -0.445 -0.316 -0.87 -0.34
Capital Expenditures -0.139 -0.445 -0.316 -0.87 -0.34
Cash From Financing Activities 96.237 102.447 247.359 17.832 55.527
Financing Cash Flow Items -2.646 -0.622
Issuance (Retirement) of Stock, Net 0.283 102.447 247.359 17.832 56.52
Issuance (Retirement) of Debt, Net 98.6 -0.371
Net Change in Cash -39.243 19.849 180.693 -10.139 41.678
Cash Interest Paid 2.697 0.04 0.027 0.062 0.001
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -52.796 -165.757 -110.949 -69.142 -31.472
Cash From Operating Activities -52.353 -135.341 -96.702 -65.516 -32.413
Cash From Operating Activities 0.08 0.327 0.246 0.161 0.077
Non-Cash Items 5.839 19.415 13.668 8.628 3.825
Cash Interest Paid
Changes in Working Capital -5.476 10.674 0.333 -5.163 -4.843
Cash From Investing Activities 0 -0.139 -0.139 -0.139 -0.12
Capital Expenditures 0 -0.139 -0.139 -0.139 -0.12
Cash From Financing Activities 24.149 96.237 96.187 66.139 0
Issuance (Retirement) of Stock, Net 24.915 0.283 0.233 0.185 0
Net Change in Cash -28.204 -39.243 -0.654 0.484 -32.533
Financing Cash Flow Items -0.766 -2.646 -2.646 -2.646
Issuance (Retirement) of Debt, Net 98.6 98.6 68.6
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Bioxcel Corp Corporation 29.2025 8546750 0 2023-09-19 LOW
Fidelity Management & Research Company LLC Investment Advisor 9.2278 2700727 -1672720 2023-09-29 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 7.0803 2072199 311516 2023-06-30 LOW
Adage Capital Management, L.P. Hedge Fund 6.6713 1952500 -129479 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 4.1262 1207622 -15370 2023-06-30 LOW
Wellington Management Company, LLP Investment Advisor/Hedge Fund 4.1116 1203344 -131262 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.8403 1123934 62954 2023-06-30 LOW
MFS Investment Management Investment Advisor/Hedge Fund 2.1305 623525 259439 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.3826 404650 21521 2023-06-30 LOW
Columbia Threadneedle Investments (US) Investment Advisor/Hedge Fund 1.194 349460 349460 2023-06-30 LOW
BofA Global Research (US) Research Firm 0.9259 270992 -69933 2023-06-30 LOW
Susquehanna International Group, LLP Investment Advisor 0.8576 250990 189009 2023-06-30 MED
Point72 Asset Management, L.P. Hedge Fund 0.8267 241958 241958 2023-06-30 HIGH
Mueller (Peter) Individual Investor 0.7947 232597 0 2023-04-27 LOW
Rafferty Asset Management LLC Investment Advisor/Hedge Fund 0.6753 197634 48522 2023-06-30 MED
Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.6304 184491 8766 2023-06-30 LOW
Votruba (Michal) Individual Investor 0.63 184375 0 2023-04-27 LOW
Charles Schwab Investment Management, Inc. Investment Advisor 0.5063 148174 4281 2023-06-30 LOW
UBS Financial Services, Inc. Investment Advisor 0.379 110936 -49353 2023-06-30 LOW
Goldman Sachs & Company, Inc. Research Firm 0.3733 109241 -18134 2023-06-30 MED

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

BioXcel Therapeutics, Inc. Company profile

About BioXcel Therapeutics Inc

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on drug development that utilizes artificial intelligence (AI) approaches to develop therapies in neuroscience and immuno-oncology. The Company's two advanced clinical development programs are BXCL501, an investigational, orally dissolving, sublingual thin film formulation of the adrenergic receptor agonist dexmedetomidine (Dex), for the treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an investigational orally administered systemic innate immune activator for the treatment of a rare form of prostate cancer and advanced solid tumors that are refractory or treatment-naive to checkpoint inhibitors.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, BioXcel Therapeutics Inc revenues was not reported. Net loss increased 30% to $106.9M. Higher net loss reflects General and administrative increase from $24.3M to $54.2M (expense), Interest income decrease of 72% to $44K (income), Interest expense increase of 48% to $40K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$3.79 to -$4.05.

Industry: Bio Therapeutic Drugs

555 Long Wharf Dr
NEW HAVEN
CONNECTICUT 06511-6107
US

Income Statement

  • Annual
  • Quarterly

News

Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

18:44, 1 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

People also watch

Gold

2,081.32 Price
-0.080% 1D Chg, %
Long position overnight fee -0.0191%
Short position overnight fee 0.0108%
Overnight fee time 22:00 (UTC)
Spread 0.30

XRP/USD

0.63 Price
-0.110% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

BTC/USD

63,540.05 Price
+0.990% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Oil - Crude

79.48 Price
-0.020% 1D Chg, %
Long position overnight fee 0.0265%
Short position overnight fee -0.0484%
Overnight fee time 22:00 (UTC)
Spread 0.030

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading